UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
(Exact name of registrant as specified in its charter)
|
| |||
(State or other jurisdiction of incorporation) |
| (Commission File Number) |
| (I.R.S. Employer |
|
| |
(Address of principal executive offices) |
| (Zip Code) |
Registrant’s telephone number, including area code: (
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each class | Trading symbol(s) | Name of each exchange on which registered |
Item 8.01 Other Events.
Blueprint Medicines Corporation (the “Company”) previously entered into: (i) a Collaboration and License Agreement, effective March 14, 2016, by and among F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc. and the Company, as amended by Amendment to Collaboration and License Agreement effective April 15, 2016 (collectively, the “Original Agreement”) and (ii) a Second Amendment to Collaboration and License Agreement, effective April 27, 2016, by and among F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc. and the Company (the “Second Amendment”). The Securities and Exchange Commission previously granted confidential treatment for certain provisions of the Original Agreement and the Second Amendment through July 5, 2021.
On July 28, 2021, in conjunction with the filing of this current report on Form 8-K, the Company is re-filing the Original Agreement and the Second Amendment to comply with the requirements set forth in Item 601(b)(10)(iv) of Regulation S-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
|
|
Exhibit No. |
| Description |
10.1† | ||
10.2† | ||
104 |
| Cover Page Interactive Data File (embedded within the Inline XBRL document and incorporated as Exhibit 101) |
† | Certain portions of this exhibit have been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K. The Company has determined that such omitted information is (i) not material and (ii) information that the Company treats as private or confidential. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
| BLUEPRINT MEDICINES CORPORATION | |
|
| |
|
| |
Date: July 28, 2021 | By: | /s/ Jeffrey W. Albers |
|
| Jeffrey W. Albers |
|
| Chief Executive Officer |
3